Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

British Journal of Cancer

Volumn 76, Issue 11, 1997, Pages 1500-1508

  Herben, V M M ^a,b   Ten Bokkel Huinink, W W ^a   Dubbelman, A C ^a   Mandjes, I A M ^a   Groot, Y ^c   Van Gortel van Zomeren, D M ^b   Beijnen, J H ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c EORTC New Drug Development Office   (Netherlands)

Author keywords

Etoposide; Pharmacokinetics; Phase I; Topoisomerase inhibitor; Topotecan

Indexed keywords

ANTINEOPLASTIC ALKALOID; ETOPOSIDE; TOPOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; MALE; NEUTROPENIA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; OVARY METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0030813205     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.585     Document Type: Article

References (41)

1. Ardizzoni A, Hansen HH, Dombernowsky P, Kaplan S, Postmus PE, Gamucci T, Schaefer B, Wanders J and Verweij J (1995) Phase II study of topotecan in refractory and sensitive small cell lung cancer (SCLC). Eur J Cancer 31A: S19
2. Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J and McGuire W (1995) Phase II trial of topotecan as salvage therapy in epithelial ovarian cancer, Proc Am Soc Clin Oncol 14: 275
3. D'Arpa P and Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163-177
4. D'Arpa P, Beardmore C and Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919-6924
5. Bertrand R, O'Connor PM, Kerrigan D and Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A: 743-748
6. Boehm JC, Hecht SM and Holden KG (1991) Water-soluble camptothecin analogs. US patent no. 5,004,758
7. Chang JY, Dethlefsen LA, Barley LR, Zhou BS and Cheng YC (1992) Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 43: 2443-2452
8. Chang AY, Garrow G, Boros L, Asbury R, Pandya K and Keng P (1995) Clinical and laboratory studies of topotecan in breast cancer. Proc Am Soc Clin Oncol 14: 105
9. Cheng M-F, Chatterjee S and Berger NA (1994) Schedule-dependent eytotoxicity of topotecan alone and in combination chemotherapeutic regimens. Oncol Res 6: 269-279
10. Clark PI, Joel SP and Slevin ML (1989) A pharmacokinetic hypothesis for the clinical efficacy of ctoposide in small cell lung cancer. Proc Am Ass Clin Oncnl 8: 66
11. Cummings J and Smyth JF (1993) DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533-543
12. DeVita VT. (1993) Principles of chemotherapy. In Principles and practice of oncology, 4th edn, DeVita VT, Hellman S and Rosenberg SA (eds), pp. 283-286, JB Lippincott: Philadelphia
13. Eckardt JR, Burris HA, Rodrigues GA, Fields SM, Rothenberg ML, Moore TD, Smith SC, Ganapathi R, Weiss GR, Johnson RK, Kuhn JG and Von Hoff DD (1993) A phase I study of the topoisomerase I and II inhibitors topotecan (T) and etoposide (E). Proc Am Soc Clin Oncol 12: 137
14. Eckardt JR, Burris HA, Von Holi DD, Rodriguez G, Fields SM, Rothenberg ML, Moore TD, Hodges S, Weiss GR, Cobb P, Rinaldi D, Kuhn JG, Ford J and Ganapathi R (1994) Measurement of tumor topoisomerase I and II levels during the sequential administration of topotecan and etoposide. Proc Am Soc Clin Oncol 13: 141
15. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowity L, DeLisa A, Donehower RC and Noe-DA (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer, Drug Metab Dispos 20: 706-713
16. Herben VMM, Ten Bokkel Huinink WW and Beijnen JH (1996) Clinical pharmacokinetics of topotecan. Clin Pharmacokin 31: 85-102
17. Holford NHG and Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16: 143-166
18. Jonkman-De Vries JD, Herben VMM, Van Tellingen O, Dubbelman AC, Ten Bokkel Huinink WW, Rodenhuis S, Bull A and Beijnen JH (1996) Oral bioavailability of low-dose (20 mg) 'home-made' etoposide capsules. Clin Drug Invest 12: 298-307
19. Kano Y, Suzuki K, Akutsu M and Suda K, Inoue Y, Yoshida M, Sakamoto S and Miura Y (1992) Fffects of CPT-I1 in combination with other anticancer agents in culture. Int J Cancer 50: 604-610
20. Kaufmann SH (1991) Antagonism between camptothecin and topoisomeruse II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129-1136
21. Kim R, Hirahayashi N, Nishiyama M, Jinushi K, Toge T and Okada K (1992) Experimental studies on biochemical modulation targeting toipoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50: 760-766
22. Kozelsky TK and Bonner JA (1995) Sequence dependent interaction of etoposide and topoteean. Proc Am Ass Cancer Res 36: 293
23. Masumoto N, Nakano S, Esaki T, Tatsumoto T, Fujishima H, Baba L, Nakamura and Niho Y (1995) Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line, Anticancer Res 15: 405-410
24. Merlin J-L (1994) Concepts of synergism and antagonism. Anticancer Res 14: 2315-2320
25. Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32: 103-108
26. Rosing H, Doyle H, Davies BE and Heijnen JH (1995) High-performance liquid chromatographic determination of the novel untitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J Chrom B 668: 107-111
27. Rosing H, Herben VMM, Van Zomeren DM, Hop E, Kettenes-Van Den Bosch JJ, Ten Bokkel Huinink WW and Beijnen JH (1997) Isolation and structural confirmation of N-des-methyl lopotecan, a metabolite of topotecan. Cancer Chemother Pharmacol (in press)
28. Rowinsky EK, Grochow LB, Hendriks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH and Donehower RC (1991) Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656
29. Rowland M and Tozer TN (1989) Clinical Pharmacokinetics: Concepts and Applications, 2nd edn, pp. 78-97 Lea and Febiger: Philadelphia
30. Saltz L, Siroit M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasoi F and Kelsen D (1993) Phase I clinical and pharmacology study of topotecan given daily tor 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85: 1499-1507
31. Sinkule JA and Evans WE (1984) High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. J Pharm Sci 73: 164-168
32. Slevin ML, Clark, PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH and Wrigley PH (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7: 1333-1340
33. Stewart CH, Baker SD, Heideman RL, Jones D, Crom WR and Pratt CB (1994) Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 12: 1946-1954
34. Sugimoto Y, Tsukahara S, Oh-Hara T, Liu LF and Tsuruo T (1990) Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962-7965
35. Takada M, Fukuoka M, Kudoh S, Masuda N, Nakagawa K, Kjshimoto S (1992) Synergistic effects of CPT-11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice. Proc Am Ass Cancer Res 33: 226
36. Tan KB, Mattern MR, Eng W-K, McCabe FL and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735
37. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC and Greco FA (1993) Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasmas: a phase I/II study. J Clin Oncol 11: 1322-1328
38. Tolcher AW, O'Shaughnessy JA, Weiss RB, Myharid RC, Schneider E, Hakim F, Noone M, Goldspiel B, Kohler D and Cowan KH (1994) A phase I study of topotecan (a topoisomerase I inhibitor) in combination with doxorubicin (a topoisomerase II inhibitor). Proc Am Soc Clin Oncol 13: 157
39. Van Warmerdam LJC, Verweij J, Schellens JHM, Rosing H, Davies BE, De Boer-Dennert M, Macs RAA and Beijnen JH (1995) Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 35: 237-245
40. Verweij J, Lund B, Beijnen J, Planting A, De Boer-Dennert M, Koier I, Rosing H and Hansen H (1993) Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 4: 673-678
41. Wang JC (1985) DNA topoisomerases. Annu Rev Riochem 4: 665-697